This clinical trial is focused on studying a condition known as acquired hemophagocytic syndrome (HS), which is a serious disorder where the body’s immune system becomes overly active and starts attacking its own tissues. The study is investigating the use of a medication called ruxolitinib, which is a type of drug known as a JAK inhibitor. This medication is being tested to see if it can help improve the condition of patients with HS who are critically ill and admitted to the intensive care unit (ICU). The goal is to determine if ruxolitinib, when used alongside standard treatments, can better reverse organ failure compared to standard treatments alone.

In this study, patients will receive either ruxolitinib or a placebo, in addition to the usual care they would receive for HS. The treatment period for ruxolitinib is up to 28 days. Other medications involved in the study include lidocaine hydrochloride monohydrate, methylprednisolone acetate, etoposide, and betamethasone sodium phosphate, which are used for various supportive treatments. The study will monitor the patients’ health, focusing on improvements in organ function and overall survival, as well as any changes in symptoms related to HS.

The trial will assess the safety of ruxolitinib in these patients and track various health indicators, such as temperature, blood cell counts, and levels of certain proteins in the blood that indicate inflammation. The primary measure of success will be a significant improvement in the patients’ organ function scores after seven days of treatment. The study aims to provide valuable insights into the potential benefits of using ruxolitinib for treating critically ill patients with acquired hemophagocytic syndrome.